Home/Pipeline/Ciltacabtagene Autoleucel (cilta-cel)

Ciltacabtagene Autoleucel (cilta-cel)

Relapsed/Refractory Multiple Myeloma

Approved / Phase 3ActiveCARTITUDE-4, CARTITUDE-5

Key Facts

Indication

Relapsed/Refractory Multiple Myeloma

Phase

Approved / Phase 3

Status

Active

Company

Legend Biotech

About Legend Biotech

Legend Biotech's mission is to discover, develop, and commercialize transformative cell therapies for patients with life-threatening diseases, primarily in oncology. Its core achievement is the successful global launch of CARVYKTI® (cilta-cel), a best-in-class CAR-T therapy for multiple myeloma, which has propelled the company to commercial leadership and validated its technology platform. The company's strategy centers on deepening its commercial footprint, advancing a broad pipeline of next-generation cell therapies, and expanding its manufacturing capabilities, all underpinned by a strategic global collaboration with Janssen (Johnson & Johnson).

View full company profile

Therapeutic Areas

Oncology Hematology

Other Relapsed/Refractory Multiple Myeloma Drugs

Drug	Company	Phase	Status
Aplidin (plitidepsin)	PharmaMar	Approved (Conditional - AU)	R&D
CAR T-Cell Therapy Program	Dr. Reddy's Laboratories	Development	Active
inobrodib + Pd (InoPd)	CellCentric	Phase 1/2	Active
TECVAYLI + DARZALEX FASPRO	Johnson and Johnson Innovative Medicine	Approved	Active
HDP-101	Heidelberg Pharma	Phase 1/2a	Active
CT053	CARsgen Therapeutics	Phase 1b/2	Active
P-BCMA-ALLO1	Poseida Therapeutics	Phase 1	Active
ABBV-383	AbbVie	Phase 1	Active
Blenrep (belantamab mafodotin)	GSK plc	Phase III	Active
bri-cel (BAY 2413334)	Bayer	Phase I	Active, recruiting
Ciltacabtagene autoleucel (Carvykti)	Genscript Biotech	Approved / Phase 3	Active
CAR-T Cell Therapy	Dr. Reddy's Laboratories	Discovery/Development	Active